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Abstract
Head and neck squamous cell carcinoma (HNSCC) is characterized by overexpression of the epidermal growth factor
receptor (EGFR) where treatments targeting EGFR have met with limited clinical success. Elucidation of the key down-
stream pathways that remain activated in the setting of EGFR blockademay reveal new therapeutic targets. The present
study was undertaken to test the hypothesis that inhibition of the mammalian target of rapamycin (mTOR) complex
would enhance the effects of EGFR blockade in HNSCC preclinical models. Treatment of HNSCC cell lines with the
newly developed TORC1/TORC2 inhibitor OSI-027/ASP4876 resulted in dose-dependent inhibition of proliferation with
abrogation of phosphorylation of known downstream targets including phospho-AKT (Ser473), phospho–4E-BP1,
phospho-p70s6K, and phospho-PRAS40. Furthermore, combined treatment with OSI-027 and erlotinib resulted in
enhanced biochemical effects and synergistic growth inhibition in vitro. Treatment of mice bearing HNSCC xenografts
with a combination of the Food andDrug Administration (FDA)-approved EGFR inhibitor cetuximab andOSI-027 demon-
strated a significant reduction of tumor volumes compared with either treatment alone. These findings suggest that
TORC1/TORC2 inhibition in conjunction with EGFR blockade represents a plausible therapeutic strategy for HNSCC.
Neoplasia (2012) 14, 1005–1014
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most
prevalent cancer worldwide. Despite innovations in surgery, chemo-
therapy, and radiation delivery, survival rates have not significantly
improved in decades. Cumulative evidence to date implicates increased
expression of the epidermal growth factor receptor (EGFR) as a prog-
nostic biomarker in HNSCC [1–3]. Successful targeting of EGFR in
preclinical HNSCC models led to the rapid clinical development of
EGFR inhibitors in this cancer, culminating in the FDA approval of
the EGFR-targeted monoclonal antibody, cetuximab, in 2006. How-
ever, despite widespread expression of EGFR in HNSCC tumors,
administration of EGFR targeting agents alone (either monoclonal
antibodies or tyrosine kinase inhibitors) have been associated with only
modest clinical responses to date [4–6]. While the mechanisms of
de novo or acquired resistance to EGFR inhibitors remain incompletely
understood, co-activation of alternative intracellular signaling pathways
may contribute to tumor growth in the setting of EGFR blockade.
We and others previously reported that persistent signaling through
G protein–coupled receptors contributes to oncogenic signaling de-
spite EGFR inhibition [7,8]. Targeting key intermediates that partic-
ipate in the cross talk between G protein–coupled receptor and EGFR
leads to additive or synergistic enhancement of tumor growth inhibi-
tion in preclinical cancer models [8,9]. Others have demonstrated that
compensatory signaling of parallel oncogenic pathways may limit the
sensitivity of cancer cells to single agents [10,11].
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Mammalian target of rapamycin (mTOR) is activated by both EGFR-
dependent and EGFR-independent pathways, including G protein–
coupled receptors, and has been implicated as a potential therapeutic
target in several solid tumors including HNSCC [9,12,13]. The mTOR
complex is comprised of two components, TORC1 and TORC2.
TORC1 includes the regulatory associated protein of mTOR (Raptor),
mammalian LST8/G protein β-subunit–like protein (mLST8/GβL),
and the more recently identified partners PRAS40 and DEPTOR [14–
16]. The most well-characterized targets of TORC1 include p70 s6
kinase 1 (p70s6K) and the eukaryotic initiation factor 4E binding
protein 1 (4E-BP1), which both serve as readouts for TORC1 activity
[17,18]. TORC2 includes the rapamycin-insensitive companion of
mTOR (Rictor), GβL, and mammalian stress–activated protein kinase
interacting protein 1 (mSIN1) [19,20]. TORC2 phosphorylates the
serine/threonine protein kinase AKT/PKB at the serine residue S473
[21]. Phosphorylation of this serine stimulates AKT phosphorylation at
a threonine T308 residue by PDK1 leading to full AKT activation [21].
TORC2 mediates TORC1 activation through AKT and TSC1/2 [22],
while TORC1 regulates TORC2 through the inhibitory effects of
p70s6K on Rictor [23].
Rapalogs, including rapamycin (sirolimus) and RAD001, are mTOR
inhibitors that are under active clinical investigation in several cancers,
including HNSCC. Both rapamycin and RAD001 bind to the cytosolic
FKBP12 protein, leading to engagement of the TORC1 complex and
attenuation of downstream TORC1 signaling [24]. However, inhibi-
tion of this complex results in attenuation of the S6K-IRS1–negative
feedback loop, which leads to stabilization of IRS1 and stimulates
phosphoinositide 3-kinase (PI3K) signaling. This triggers an increase
in AKT phosphorylation, activating AKT-mediated cell survival while
inhibiting p70s6K-mediated cell proliferation [10]. Thus, inhibition of
TORC1 pathways with concomitant activation of TORC2 pathways
represents a potential limitation of rapalogs.
OSI-027 (also known as A7486) is an orally available mTOR inhib-
itor that competitively binds to the adenosine triphosphate (ATP)-
binding domain of mTOR, inhibiting both mTOR complexes.
This dual TORC1/TORC2 inhibitory function of OSI-027 presents
several advantages compared with rapalogs by decreasing signaling
through TORC1-mediated mechanisms. OSI-027 is currently under-
going early phase clinical testing. The present study was undertaken
to investigate the activity of OSI-027 alone or in combination with
EGFR inhibitors in HNSCC preclinical models. Our results suggest
that both TORC1 and TORC2 signaling are inhibited by OSI-027 in
a dose-dependent fashion in a panel of HNSCC cell lines. We also
show that combined treatment with OSI-027 and erlotinib result in
significant decreases in TORC1 and TORC2 signaling and synergistic
inhibition of in vitro proliferation compared to either drug alone. Fur-
thermore, the combination of OSI-027 and cetuximab demonstrate
significantly improved antitumor efficacy compared with either treat-
ment alone in an HNSCC xenograft model. These cumulative find-
ings suggest that OSI-027 may be used in combination with EGFR
inhibitors to improve treatment responses.
Materials and Methods
Cell Lines, Tumors, and Reagents
Human HNSCC cell lines included UMSCC1 [25], a kind gift
from Dr Thomas Carey (University of Michigan, Ann Arbor, MI),
Cal 33 from Dr Gerard Milano (Centre Antoine Lacassagne, Nice,
France) [26], 686LN from Dr Georgia Chen (Emory University,
Atlanta, GA), and FaDu from Dr Jeffrey N. Myers (The University
of Texas MD Anderson Cancer Center, Houston, TX) [27]. UPCI-
15B, Cal 33, and UMSCC1 cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) with
10% heat-inactivated FBS (Invitrogen). FaDu cells were maintained
in DMEM with 10% FBS and 1% nonessential amino acids. 686LN
cell lines were maintained in DMEM/F12 with 10% FBS. All cells
were incubated at 37°C in the presence of 5% CO2. All cell lines were
validated through genotyping with AmpF/STR Identifiler PCR Am-
plification Kit (Applied Biosystems, Carlsbad, CA). OSI-027 (also
known as A7486) and erlotinib were provided byOSI-Pharmaceuticals,
Inc (Farmingdale, NY; now Astellas Pharma, Deerfield, IL).
Cytotoxicity Assays
One day prior to treatment, UMSCC1, Cal 33, and FaDu cells
were plated at a density of 2 × 104 cells/ml in 96-well plates. Cells
were treated with half-log concentrations of OSI-027 from 0.3 nM
to 10 μM, rapamycin from 0.3 μM to 30 μM, and erlotinib from
0.1 μM to 8 μM. After 3 days, cell viability was determined using
CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison,
WI). Variable-slope sigmoidal curves were plotted and EC50 values
were computed through nonlinear regression analysis in GraphPad
Prism software (GraphPad Software Inc, La Jolla, CA).
Immunoblot Analysis
HNSCC cells UMSCC1 and Cal 33 were plated at a density of 1 ×
106 cells/dish in 100-mm petri dishes 1 day prior to treatment. Cells
were treated with 0.3, 0.5, 0.75, 1.0, or 1.25 μM OSI-027. DMSO
controls were included. For combined treatment with OSI-027 and
erlotinib, UMSCC1 cells were treated with 0.5 μM OSI-027, 3 μM
erlotinib, or both. Cal 33 cells were treated with 0.5 μM OSI-027,
4.0 μM erlotinib, or both. DMSO controls were included. After
24 hours, cells were lysed as described previously [28]. Protein levels
were determined using the Bio-Rad protein assay method (Bio-Rad
Laboratories, Hercules, CA). Forty micrograms of protein was resolved
on 10% sodium dodecyl sulfate–polyacrylamide gels and transferred to
nitrocellulose membranes using the semidry transfer machine (Bio-
Rad Laboratories). Membranes were blocked with Odyssey Blocking
Buffer (Li-COR Biosciences, Lincoln, NE) for 1 hour at room tem-
perature and incubated with primary antibodies in 5% BSA in Tris-
buffered saline with Tween 20 (TBS-T) solution overnight at 4°C.
After washing with TBS-T three times, membranes were incubated
for 1 hour with IRDye 800CW goat anti-rabbit or IRDye 680LT goat
anti-mouse secondary antibody (Li-COR Biosciences) diluted 1:5000 in
5% BSA in TBS-T. Membranes were rinsed with TBS-T three times
and scanned with the Odyssey Infrared Imaging System (Li-COR Bio-
sciences). Densitometry was performed with ImageJ software (National
Institutes of Health, Bethesda, MD). The following monoclonal anti-
bodies from Cell Signaling Technology (Danvers, MA) were used at a
dilution of 1:1000 in 5% BSA in TBS-T: phospho-p70s6K (Thr389)
(rabbit, No. 9205); p70s6K (rabbit, No. 9202); phospho-AKT
(Ser473) (mouse, No. 4051S); AKT (rabbit, No. 9272); phospho-
PRAS40 (Thr246) (rabbit, No. 2997); PRAS40 (rabbit, No. 2691);
phospho–4E-BP1 (Thr37/46) (rabbit, No. 2855); 4E-BP1 (rabbit,
No. 9452). β-Tubulin rabbit antibody (AbCam, Cambridge, United
Kingdom) diluted 1:5000 was used as a loading control.
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Synergy Studies
The method of Chou and Talalay [29] was used to determine
levels of interaction between OSI-027 and erlotinib. Combination
index (CI) values were determined using Calcusyn software (Biosoft,
Cambridge, United Kingdom) at 50% inhibition of cell growth.
Synergy was indicated by a CI of <1, additivity by a CI equal to 1,
and antagonism by a CI of >1.
Clonogenic Studies
Cal 33 or UMSCC1 cells were plated the day before treatment at
5000 cells per well in a six-well plate. The next day, cells were treated
with the EC50 values of each drug for each cell line. Cal 33 cells were
treated either with 3 μM erlotinib, 0.5 μM OSI-027, or a combina-
tion of both drugs. A DMSO control was included. UMSCC1 cells
were treated with 4 μM erlotinib, 0.5 μM OSI-027, or a combina-
tion of both drugs. A DMSO control was also included. Cells were
allowed to form colonies for 5 days. These cells were then washed in
phosphate-buffered saline and stained in crystal violet. Colonies of
cells containing 50 cells or greater were counted. Experiments were
repeated three times for each cell line.
In Vivo Studies
Female athymic nude mice, 5 to 6 weeks old, were purchased from
Harlan (Indianapolis, IN) and maintained in a pathogen-free facility.
Animal care was in compliance with the University of Pittsburgh’s In-
stitutional Animal Care and Use Committee. Mice were inoculated
subcutaneously with a 100-μl suspension of 5 × 105 cells in Hanks’
balanced salt solution subcutaneously in the left flank. Tumor-bearing
mice were randomized to receive 0.02 mg of cetuximab (n = 10)
i.p. twice a week, OSI-027 through oral gavage daily at 50 mg/kg
daily (n = 10), a combination of cetuximab plus OSI-027 (n = 10),
or vehicle alone (trappsol 20% through oral gavage and saline i.p.;
n = 9). Tumors were measured with a vernier caliper thrice per week
and the volume was calculated through use of the equation volume =
length × (width)2/2. Tumors were harvested at the end of the study
and fixed in 10% formalin before paraffin embedding. Tumor sec-
tions were assessed for Ki67 and terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) immunohistochemical staining
by a pathologist (L.W.) blinded to the treatment groups. The percent
positive Ki67 staining and the average number of TUNEL-positive
cells were determined for each tumor.
Statistical Analysis
In vitro and in vivo data were analyzed using nonparametric Kruskal-
Wallis exact test with Cytel Studio 9.
Results
OSI-027 Inhibits HNSCC Growth In Vitro in a
Dose-dependent Manner
Rapalogs (including rapamycin) have demonstrated limited cellular
cytotoxicity in HNSCC cell lines with reported EC50 values of 5, 12,
and 20 μM for the HNSCC cell lines SCC61, SQ20B, and HEP2,
respectively [30]. We performed EC50 determinations for rapamycin
in a panel of HNSCC cell lines and found similar ranges with EC50
values ranging from 6 to 20 μM across a panel of five HNSCC cell
lines (Figure 1A). To determine the antiproliferative effects of the
selective TORC1/2 inhibitor OSI-027 in a panel of HNSCC cell
Figure 1. HNSCC cells are more sensitive to growth inhibition by OSI-027 than rapamycin. Representative HNSCC cell lines (PCI-15B,
Cal 33, UMSCC1, 686LN, and FaDu) were plated at a density of 5000 cells in 100 μl in each well of a 96-well plate. Cells were treated for
3 days in triplicate with either (A) rapamycin or (B) OSI-027 followed by CellTiter-Glo Assay. For each cell line, EC50 values were obtained
three times with similar results.
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lines compared to rapamycin, we treated the same cells with increasing
concentrations of OSI-027 followed by assessments of cell growth
72 hours after the addition of the agent. As shown in Figure 1B,
OSI-027 exhibited reproducible dose-dependent cytotoxicity with
EC50s in the nanomolar to low micromolar range. These values are
consistent with the concentrations reported in leukemic and other
solid tumor cell lines [31,32] and suggest that OSI-027 inhibits
HNSCC cell line proliferation, more potently than rapamycin.
OSI-027 Inhibits TORC1 and TORC2 Downstream Targets
in a Dose-dependent Manner in HNSCC Cell Lines
Previous studies of mTOR inhibition in HNSCC models have gen-
erally used rapalogs such as rapamycin or RAD-001 [33–37]. OSI-027,
a novel inhibitor of the ATP-binding pocket, has not been studied
in HNSCC. To evaluate the potency of OSI-027 in HNSCC pre-
clinical models, we treated representative HNSCC cells (Cal 33 and
UMSCC1) with a range of concentrations of OSI-027 (0.3–1.25 μM)
for 24 hours followed by biochemical assessment of expression of total
and phosphorylated forms of TORC1 and TORC2 substrates. As
shown in Figure 2, treatment of HNSCC cells with increasing con-
centrations of OSI-027 was associated with decreased phosphorylation
of downstream TORC1 and TORC2 signaling proteins, indicating
mitigation of mTOR signaling by this compound. To determine if
OSI-027 more potently decreased TORC1/2 signaling in HNSCC
compared with rapalog treatment, we assessed activation of phospho-
AKT (Ser473) in UMSCC1 and Cal 33 cells treated with EC50 concen-
trations of OSI-027 or rapamycin. As shown in Figure 2C , OSI-027
reduced expression of phospho-AKT (Ser473) at much lower concen-
trations (0.5 μM) compared to rapamycin (13 μM).
Combined Treatment with OSI-027 and Erlotinib Results
in Synergistic Inhibition of HNSCC Cell Survival
Targeting two pathways that both contribute to cell survival can
lead to additive or synergistic growth inhibition. Rapamycin has been
shown to synergize with erlotinib in a variety of solid tumors [10]. We
have shown that the combination of RAD001, a TORC1 inhibitor,
in combination with erlotinib resulted in enhanced decreases in cell sur-
vival, but these effects were only additive [38]. To determine the anti-
Figure 2. OSI-027 inhibits TORC1 and TORC2 downstream targets in a dose-dependent manner in HNSCC cell lines. HNSCC cells
(A) UMSCC1 and (B) Cal 33 were treated for 24 hours with increasing concentrations of OSI-027 (0.3, 0.5, 0.75, 1, and 1.25 μM) or
DMSO as a control. Western blot analysis was then performed for phosphorylated and total levels of p70s6K, AKT (Ser473), PRAS40,
and 4EBP1. β-Tubulin was included as a loading control. (C) HNSCC cells (UMSCC1 and Cal 33) were treated with EC50 values of OSI-027
(0.5 μM for UMSCC1 and Cal 33) or rapamycin (13 μM for UMSCC1 and 20 μM for Cal 33). DMSOwas used as a vehicle control. Cells were
treated for 24 hours followed byWestern blot analysis for phospho-AKT (Ser473) and total AKT. β-Tubulin was included as a loading control.
The experiment was repeated three times with similar results.
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survival effects of combined TORC1/2 and EGFR inhibition, we
performed clonogenic assays using OSI-027 and erlotinib. Representa-
tive HNSCC cells (UMSCC1 and Cal 33) were treated with 0.5 μM
OSI-027 or erlotinib (3 μM for UMSCC1 and 4 μM for Cal 33) or
a combination of OSI-027 plus erlotinib for 5 days followed by assess-
ment of colony formation. As shown in Figure 3, A and E , inhibition
of both EGFR and TORC1/2 pathways demonstrated a significantly
reduced number of colonies compared with either agent alone (Cal 33,
P = 0.0004; UMSCC1, P = 0.0003).
To further investigate the enhanced antiproliferative effects of
OSI-027 and erlotinib in HNSCC cell lines, we treated UMSCC1
and Cal 33 cells with decreasing half-log concentrations of OSI-027,
erlotinib, or a combination of the two drugs. CellTiter-Glo Assay was
then performed and the data were analyzed by the method of Chou
and Talalay. As shown in Figure 3, B and F , dose-response graphs show
an enhanced effect. We also demonstrate that this effect was synergistic,
as isobolograms show combination points well into the synergistic range
for ED90, ED75, and ED50 inhibition (Figure 3, C and G ). Addi-
tionally, at each combination of OSI-027 and erlotinib, CI values for
each data point were less than 1.0 over a range of drug concentrations
that included the EC50s of both drugs (Figure 3, D and H).
Combined Treatment with OSI-027 and Erlotinib
Enhances Inhibition of TORC1 and TORC2
Downstream Targets in HNSCC Cell Lines
Rapalogs have been combined with EGFR inhibitors in solid tumor
cell lines and xenografts and have been shown to enhance the anti-
tumor effects of EGFR inhibitors such as erlotinib [10]. However,
the combined effect of OSI-027 and EGFR inhibitors has not pre-
viously been studied in HNSCC. Allosteric mTORC1 inhibitors com-
bined with EGFR inhibitors resulted in enhanced down-regulation of
TORC1 markers. However, this combination was shown to increase
AKT phosphorylation [10,39]. To determine the biochemical con-
sequences of targeting both TORC1 and TORC2 in conjunction
with EGFR in HNSCC cells, representative cell lines (UMSCC1 and
Cal 33) were treated with half of the EC50 concentrations of OSI-027
Figure 3. Combined treatment with OSI-027 and erlotinib results in synergistic inhibition of cell survival. HNSCC cells (A–D) UMSCC1
and (E–H) Cal 33 were plated in 96-well plates at a density of 1000 cells per well in four wells of a six-well plate in DMEM + 10% FBS. The
next day, cells were treated with 0.5 μM OSI-027, erlotinib (3 μM for UMSCC1 cells and 4 μM for Cal 33 cells), or a combination of both
drugs at these concentrations for 5 days. Differences in treatment groups were tested through the Kruskal-Wallis exact test (Statxact
software, Version 7). Dose-effect curves and isobolograms demonstrate synergistic effects of combined treatment. Synergy was deter-
mined using the CI values of Chou and Talalay with values less than 1 indicating synergy. The experiment was repeated at least three times
with similar results.
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(0.5 μM) and/or erlotinib (3 μM for UMSCC1 and 4 μM for Cal 33)
for 24 hours followed by immunoblot analysis. As shown in Figure 4, A
and B, combined inhibition of EGFR and TORC1/2 resulted in a
significant decrease in the activation of both TORC1 and TORC2
substrates when compared to either treatment alone or DMSO control
(UMSCC1: P = 0.0014 for phospho-AKT (Ser473), P = 0.00006
for phospho-p70s6K, and P = 0.003 for phospho-PRAS40; Cal 33:
P = 0.006 for phosho-AKT (Ser473), P = 0.014 for phospho-p70s6K,
and P = 0.038 for phospho-PRAS40).
The Combination of OSI-027 and Cetuximab Significantly
Enhances Antitumor Effects in HNSCC In Vivo
OSI-027 was recently reported to demonstrate superior inhibition
of tumor growth in breast and colon cancer models compared with
rapamycin [31]. Others have shown a decrease in tumor burden when
mice bearing human tumor xenografts were treated with a combination
of rapamycin and erlotinib [10]. Treatment of HNSCC xenografts with
rapalogs in combination with EGFR inhibition has demonstrated only
modest enhanced effects [38,40]. Given the superior antiproliferative
and biochemical effects of TORC1/TORC2 inhibition in combination
with EGFR blockade in vitro, we next assessed the in vivo effects using
cetuximab, which is FDA approved for the treatment of HNSCC.
Mice were inoculated with a representative HNSCC cell line, Cal 33,
randomized to one of four treatment groups including control (n = 9),
OSI-027 alone (50 mg/kg daily by oral gavage, n = 10), cetuximab
alone (0.02 mg twice/week, i.p., n = 10), or a combination of both
OSI-027 and cetuximab using the same concentrations and dosing
schedules (n = 10). As shown in Figure 5A, starting on day 9, tumor vol-
umes were significantly decreased in the group receiving both OSI-027
plus cetuximab combined treatment compared to either treatment
alone or vehicle control (P = 0.001). In addition, we examined Ki67
labeling and TUNEL staining in the xenografts and found that Ki67
labeling was reduced by treatment with cetuximab alone or combined
cetuximab plus OSI-027 compared with vehicle control or OSI-027
alone (Figure 5B). TUNEL staining was decreased in all treatment
groups (compared with vehicle control) to a similar degree (Figure 5C).
Discussion
EGFR is upregulated in HNSCC where expression levels generally
correlate with decreased survival. Despite extensive evidence of the
antitumor effects of EGFR targeting in HNSCC preclinical models,
EGFR inhibition to date has been associated with limited clinical
benefit. One plausible mechanism for the modest activity of EGFR
inhibitors is the compensatory activation of alternative signaling path-
ways in the setting of EGFR blockade [10]. It has been demonstrated
in a variety of cancers that EGFR inhibition results in increased AKT
phosphorylation with subsequent mTOR activation [40,41]. In fact,
while mTOR itself is infrequently mutated in most cancers, hyper-
activation of mTOR can be detected in many tumors or cell lines,
including those characterized by mutations of PI3K or AKT or loss
of PTEN [42–44]. Targeting mTOR in conjunction with EGFR
represents a rational approach to abrogate increased activation through
the PI3K-AKT-mTOR pathway.
The results of the present study demonstrated that all HNSCC cell
lines tested were sensitive to the antiproliferative effects of TORC1/
TORC2 inhibition using OSI-027 with EC50 values ranging from
Figure 3. (continued).
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0.45 to 4.2 μM. In addition, growth inhibition was accompanied by
decreased activation of downstream biochemical markers of TORC1
and TORC2 in a dose-response manner, demonstrating that not only
does OSI-027 decrease growth but also does so in a manner that is con-
sistent with its putative mechanism of action. Combined treatment of
HNSCC cells with OSI-027 and erlotinib further decreased TORC1
and TORC2 activation when compared to either treatment alone.
Using the method of Chou and Talalay, combinations of OSI-027
and erlotinib resulted in synergistic inhibition of HNSCC cell prolifer-
ation. In vivo studies using the FDA-approved EGFR targeting agent
cetuximab demonstrated enhanced antitumor effects, suggesting that
EGFR inhibition in combination with TORC1/TORC2 blockade is
a plausible therapeutic strategy for the treatment of HNSCC.
In leukemic cell lines, TORC1/TORC2 blockade demonstrated
improved antitumor effects compared with TORC1 inhibition using
rapamycin [41]. While rapamycin was effective at a growth inhibitory
concentration (GI) of 6.5 nM, it reached a plateau efficacy at 60%
[41]. The combined TORC1/2 inhibitor PP242 suppressed growth
by 90%, still maintaining a GI in the low nanomolar range in leukemic
cells (12 nM) [41]. In the same study, similar results were observed
for the combined PI3K-TORC1/2 inhibitor PI-103 (GI of 86 nM).
These findings suggest that leukemic cell lines are more sensitive to
the effects of dual TORC1/2 compared with TORC1 inhibition
alone. In another study, the TORC1/2 inhibitor Ku-0063794 showed
similar efficacy to PP242 with a GI in the nanomolar range in a leu-
kemic cell line [45]. Vakana et al. reported that, in Ph+ leukemias,
OSI-027 inhibited proliferation in both imatinib-sensitive and imatinib-
resistant cells [46]. In the only prior study of OSI-027 in solid tumor
models (but not HNSCC), IC50 values ranged from 0.5 to 4.5 μM
[31]. We found similar EC50 values for all five HNSCC cell lines tested
(0.45–4.2 μM). In the present study, we found that OSI-027 potently
inhibited HNSCC cell proliferation at EC50 ranges far below those
previously reported for single-arm TORC inhibitors such as rapamycin
[30]. Our own investigation into the efficacy of rapamycin corrobo-
rates the ability of OSI-027 to inhibit growth at lower rapamycin con-
centrations ranging from 6.5 to 20 μM in HNSCC. These results
indicate that dual targeting of TORC1 and TORC2 may be more
efficacious in solid tumors such as HNSCC, compared with TORC1
inhibition alone. The biochemical effects of combined TORC1/2
inhibition have been reported to consist of dose-dependent decreases
Figure 4. Combined treatment with OSI-027 and erlotinib enhances inhibition of TORC1 and TORC2 downstream targets in HNSCC cell
lines. HNSCC cells (A) UMSCC1 and (B) Cal 33 were treated with (0.5 μM for UMSCC1 and Cal 33), erlotinib (3 μM for UMSCC1 and
4 μM for Cal 33), or a combination of the two drugs at these concentrations. DMSOwas used as a control. Cells were treated for 24 hours
followed by Western blot analysis for known TORC1 and TORC2 substrates. Cells were probed for phospho-AKT (Ser473) and total
AKT, phospho-PRAS40 and total PRAS40, phospho-p70s6K and total p70s6K, and phospho–4E-BP1 and total 4E-BP1. Differences in treat-
ment groups were tested through the Kruskal-Wallis exact test (Statxact software, Version 7). β-Tubulin was included as a loading control.
Experiments were repeated three times with similar results.
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in the expression of downstream markers of TORC1/TORC2 with
complete inhibition at the highest concentrations. Treatment of leu-
kemic cells with 1 μM PP242 nearly completely abrogated expres-
sion of the mTOR downstream markers pAKT, phospho-p70, and
phospho-mTOR (s2481) [47]. Similarly, others have shown decreased
activation of both TORC1/2 markers in murine embryonic fibroblasts
(MEFs) using a combined inhibitor, Torin1 [48]. Kinase assays to eval-
uate inhibition of both mTORC1 and mTORC2 reveal that, in the
presence of Ku-0063794, levels of phosphorylated p70s6K, a marker
for TORC1, decreased in a dose-dependent fashion [45]. Similar results
were obtained for Ku-0063794 and AKT (s473), a marker for TORC2
[45]. In the few reports to date describing OSI-027, treatment of leu-
kemic cell lines with OSI-027 was associated with decreased expression
of markers for TORC1 and TORC2 activation [49]. Other studies re-
port that in primary AML leukemic blasts, cells treated with OSI-027
showed a decrease in activation of TORC1 and TORC2 markers, in-
cluding S6K and AKT (Ser473), respectively [32]. A variety of leukemic
cell lines demonstrated decreased activation of mTORC1/2 markers
in cells treated with OSI-027 [50]. In that study, OSI-027, unlike
rapamycin, also decreased expression of 4E-BP-1 [50].
In another report assessing OSI-027 in solid tumor models, com-
plete knockdown of both TORC1 and TORC2 markers was only
observed at the highest concentration tested (10 μM) [31]. In the
present study, we demonstrate that OSI-027 targets both mTORC1
and mTORC2 in HNSCC cell lines in conjunction with a dose-
dependent decrease in activation of both TORC1 (levels of phospho-
p70s6K) and TORC2 [levels of 4E-BP1, AKT (Ser473), and PRAS40].
Our findings suggest that combined inhibition of TORC1/TORC2
may be efficacious in solid tumors through predicted biochemical
mechanisms at achievable concentrations in vivo.
Figure 5. Combination of OSI-027 and cetuximab results in enhanced antitumor effects in vivo. Athymic nude mice were inoculated
subcutaneously with 5 × 105 Cal 33 cells. After tumors were palpable, 39 mice were randomized into four groups and treated with either
vehicle (n = 9), OSI-027 (n = 10; dose of 50 mg/kg daily, by oral gavage), cetuximab (n = 10; dose of 0.02 mg twice per week, i.p.), or
a combination of cetuximab and OSI-027 (n = 10; above dosages). Tumor volumes were measured three times a week for 14 days.
(A) Combined treatment with OSI-027 and C225 significantly reduced tumor growth compared to single agents alone (P = 0.001). Dif-
ferences in treatment groups were tested through the Kruskal-Wallis exact test (Statxact software, Version 7). Xenograft tumors were
assessed for (B) percent Ki67-positive cells and (C) average number of TUNEL-positive cells per high power field.
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Previous studies have found enhanced effects of combining TORC
inhibitors with an EGFR inhibitor in preclinical cancer models.
Combinations of rapamycin and either imatinib or dasatinib resulted
in enhanced (and even synergistic) decreases in mTOR activation
models of acute leukemia harboring the Philadelphia chromosome
[10,41]. In addition, combinations of TORC1/TORC2 inhibition
using PP242 and either imatinib or dasatinib resulted in further de-
creases in TORC1/2 activation in Ph(+) leukemic cells compared to
either agent alone or the combination of rapamycin and imatinib [41].
In contrast to hematopoietic malignancies, EGFR is an established
therapeutic target in several solid tumors, including HNSCC. Despite
ubiquitous expression of EGFR in HNSCC, EGFR targeting to date
has resulted in limited clinical benefit unless combined with cytotoxic
chemotherapy and/or radiation [51]. There are no reports examining
the therapeutic mechanisms of EGFR inhibition in combination with
TORC1/2 blockade in any cancer, including a cancer where EGFR
is an established therapeutic target, such as in HNSCC. The results
of the present study show, for the first time, that a combination of
erlotinib and OSI-027 results in synergistic antiproliferative effects
in vitro and that combined inhibition of EGFR and TORC1/TORC2
in vivo using the clinical inhibitor cetuximab results in significantly
enhanced antitumor effects. One of the limitations of this data is
that treatment was initiated when tumors were at a median volume of
48 mm3. In general, in vivo therapeutic agents are less effective when
initiated in the setting of larger tumor volumes given the limited vascular
supply in subcutaneous xenografts. Further, HNSCC tumor volumes
in control mice approach the maximal limits permitted by the Institu-
tional Animal Care and Use Committee making it difficult to acquire
multiple measures of comparative tumor volumes. Another limitation
of the study is that long-term effects of over 30 days of therapy to
study mechanisms of resistance could not be assessed because of the
short duration of the study. To address this limitation, we performed
a similar in vivo therapeutic study using HNSCC cell line FaDu,
where tumor-bearing mice were treated with OSI-027 and/or C225
for 14 days with additional observation and measurements through
33 days. However, tumor growth was inhibited by the combination
throughout the dosing period, so assessment of mechanisms of resis-
tance would not be supported by these studies (data not shown).
Levels of activated TORC1 markers were significantly decreased in
HNSCC cells treated with erlotinib plus OSI-027 compared to either
drug alone. Levels of TORC2 markers were similarly decreased to a
greater extent in cells treated with both inhibitors (Figure 4). Clono-
genic studies reveal a significant difference (P < 0.05) in the number
of colonies after 5 days of treatment in the combination-treated group
when compared to single agent(s) alone (Figure 3, A and E). A prior
study investigating the antitumor effects of any tyrosine kinase inhib-
itor (TKI) with a TORC1/TORC2 inhibitor in vitro demonstrated
synergistic growth inhibition in leukemic cells treated with a combi-
nation of PP242 in combination with imatinib or dasatinib compared
with either agent alone [41]. In contrast to our findings, synergistic
effects were much more pronounced when either TKI was combined
with rapamycin [41].
Yu et al. recently reported a phosphoproteomic analysis of mTOR
downstream signaling networks where mTOR was found to influence
its upstream targets by mediating the activities of receptor-tyrosine
kinases. Growth factor receptor–bound protein (grb10) showed de-
creased phosphorylation when cells were treated with rapamycin,
revealing a novel downstream partner of mTORC1. Furthermore, it
was determined that grb10 is directly phosphorylated by mTORC1
and is not phosphorylated by any upstream molecules when mTOR is
activated [52]. Other phosphoproteomic studies following treatment
with Torin1 in human embryonic kidney–293 cells that overexpress
mTORC1 also showed that grb10 contributed to mTOR signaling [53].
The present study is one of the first to examine the effects of
OSI-027 in combination with EGFR targeting strategies in tumor
models where EGFR inhibition is an FDA-approved therapeutic
strategy. We hypothesized that because EGFR and mTOR signal-
ing contribute to HNSCC cell survival through both interacting and
independent pathways, combined inhibition may improve treat-
ment responses. Our findings that OSI-027 synergizes with erlotinib
to decrease HNSCC survival in vitro and enhances the effects of
cetuximab in vivo suggests that there is a rational basis for further
research of TORC1/2 inhibitors such as OSI-027 for the treatment
of solid tumors such as HNSCC.
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